feb 12, 2018: 1 p.m. - 1:55 p.m.
The policy shifts announced by the CFDA and Chinese investment authorities within the past two years have unlocked significant new opportunities for biopharma companies to access the patient population in China and obtain capital from new sources. Already the world’s second largest market for biopharmaceuticals, the increasing pace of drug reviews and harmonization of clinical trials expectations means companies should revisit their market launch prioritizations. This session will share advice from successful leaders in this market for partnering with Chinese biopharmas and investors.
Moderator: Joseph Damond, Executive Vice President, International Affairs, Biotechnology Innovation Organization (BIO)
Alex Jung, Managing Director, Parthenon-EY, Ernst & Young LLP
Michael Keyoung, MD, PhD, Managing Director and Head of North America, C-Bridge Capital
Yuwen Liu, Founding Partner, BOHE Angel Fund; former Chairwoman & CEO, Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY)
Hummer Mars, Executive Director, China Group, Global Investment Banking Division, NYIC
Kimberly Nearing, Managing Director, Head of Life Sciences, Cedrus Group
Dan Zhang, MD, Chairman, Fountain Medical Development